BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1613 related articles for article (PubMed ID: 17951308)

  • 1. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.
    Bergesio F; Ciciani AM; Manganaro M; Palladini G; Santostefano M; Brugnano R; Di Palma AM; Gallo M; Rosati A; Tosi PL; Salvadori M;
    Nephrol Dial Transplant; 2008 Mar; 23(3):941-51. PubMed ID: 17951308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal involvement in systemic amyloidosis--an Italian retrospective study on epidemiological and clinical data at diagnosis.
    Bergesio F; Ciciani AM; Santostefano M; Brugnano R; Manganaro M; Palladini G; Di Palma AM; Gallo M; Tosi PL; Salvadori M;
    Nephrol Dial Transplant; 2007 Jun; 22(6):1608-18. PubMed ID: 17395661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Renal involvement in amyloidosis. Clinical outcomes, evolution and survival].
    Esteve V; Almirall J; Ponz E; García N; Ribera L; Larrosa M; Andreu X; García M
    Nefrologia; 2006; 26(2):212-7. PubMed ID: 16808259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal amyloidosis followed more than 5 years: report of 12 cases.
    Kaaroud H; Boubaker K; Béji S; Abderrahim E; Moussa FB; Turki S; Goucha R; Hedri H; El Younsi F; Kheder A; Maiz HB
    Transplant Proc; 2004; 36(6):1796-8. PubMed ID: 15350480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
    Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
    Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
    Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
    Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy options in systemic AL-amyloidosis with renal involvement].
    Hetzel GR; Schneider P; Mondry A; Heering P; Heyll A; Grabensee B
    Dtsch Med Wochenschr; 2000 Aug; 125(34-35):997-1002. PubMed ID: 11004911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients.
    Gertz MA; Kyle RA; O'Fallon WM
    Arch Intern Med; 1992 Nov; 152(11):2245-50. PubMed ID: 1444684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.
    Bird JM; Fuge R; Sirohi B; Apperley JF; Hunter A; Snowden J; Mahendra P; Milligan D; Byrne J; Littlewood T; Fegan C; McQuaker G; Pagliuca A; Johnson P; Rahemtulla A; Morris C; Marks DI;
    Br J Haematol; 2006 Aug; 134(4):385-90. PubMed ID: 16822294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney.
    Gertz MA; Leung N; Lacy MQ; Dispenzieri A; Zeldenrust SR; Hayman SR; Buadi FK; Dingli D; Greipp PR; Kumar SK; Lust JA; Rajkumar SV; Russell SJ; Witzig TE
    Nephrol Dial Transplant; 2009 Oct; 24(10):3132-7. PubMed ID: 19403931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic dialysis in patients with systemic amyloidosis: the experience in northern Italy.
    Moroni G; Banfi G; Montoli A; Bucci A; Bertani T; Ravelli M; Pozzi C; Leonelli M; Lupo A; Volpi A
    Clin Nephrol; 1992 Aug; 38(2):81-5. PubMed ID: 1516284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience.
    Ozawa M; Komatsuda A; Ohtani H; Nara M; Sato R; Togashi M; Takahashi N; Wakui H
    Clin Exp Nephrol; 2017 Apr; 21(2):212-227. PubMed ID: 27116248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Among therapy modalities of end-stage renal disease, renal transplantation improves survival in patients with amyloidosis.
    Ozdemir BH; Ozdemir FN; Sezer S; Sar A; Haberal M
    Transplant Proc; 2006 Mar; 38(2):432-4. PubMed ID: 16549140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation.
    Leung N; Dispenzieri A; Lacy MQ; Kumar SK; Hayman SR; Fervenza FC; Cha SS; Gertz MA
    Clin J Am Soc Nephrol; 2007 May; 2(3):440-4. PubMed ID: 17699449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary systemic amyloidosis with delayed progression to multiple myeloma.
    Rajkumar SV; Gertz MA; Kyle RA
    Cancer; 1998 Apr; 82(8):1501-5. PubMed ID: 9554527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure.
    Maurer MS; Raina A; Hesdorffer C; Bijou R; Colombo P; Deng M; Drusin R; Haythe J; Horn E; Lee SH; Marboe C; Naka Y; Schulman L; Scully B; Shapiro P; Prager K; Radhakrishnan J; Restaino S; Mancini D
    Transplantation; 2007 Mar; 83(5):539-45. PubMed ID: 17353770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Secondary amyloidosis (AA) and renal disease].
    Torregrosa E; Hernández-Jaras J; Calvo C; Ríus A; García-Pérez H; Maduell F; Vera JM
    Nefrologia; 2003; 23(4):321-6. PubMed ID: 14558331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome.
    Mollee PN; Wechalekar AD; Pereira DL; Franke N; Reece D; Chen C; Stewart AK
    Bone Marrow Transplant; 2004 Feb; 33(3):271-7. PubMed ID: 14647248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.
    Perfetti V; Siena S; Palladini G; Bregni M; Di Nicola M; Obici L; Magni M; Brunetti L; Gianni AM; Merlini G
    Haematologica; 2006 Dec; 91(12):1635-43. PubMed ID: 17145600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 81.